Competition Is Brewing Between ADCs and Bispecifics

Why It Matters

Their outcomes will shape the market share of ADCs versus bispecifics and influence treatment sequencing, payer decisions, and future oncology R&D investments.

Key Takeaways

• sac‑TMT cuts progression risk 65% vs Keytruda alone
• ivonescimab reduces death risk 34% and 79% 12‑month survival
• Both agents in fast‑track FDA review, market entry imminent
• ADCs target TROP‑2, enabling multiple cancer indications
• Combination strategies may merge ADCs and bispecifics in therapy

Pulse Analysis

Antibody‑drug conjugates (ADCs) and bispecific antibodies have become the two most heavily funded pillars of modern oncology, attracting billions of dollars in venture capital and corporate M&A. ADCs, exemplified by Daiichi Sankyo’s Enhertu, marry a potent cytotoxic payload with a tumor‑targeting antibody, promising "smart chemo" that spares healthy tissue. Bispecifics, such as Summit Therapeutics’ ivonescimab, simultaneously engage two distinct antigens—PD‑1 and VEGF—to amplify immune response. This dual‑modality race reflects a broader industry shift toward precision‑engineered biologics that can tackle historically undruggable pathways.

At the recent ASCO meeting, the data underscored divergent strengths. Sac‑TMT, paired with Merck’s Keytruda, slashed disease‑progression risk by 65% in a phase 3 Chinese NSCLC trial, highlighting the ADC’s ability to deliver a high‑payload payload while leveraging an established checkpoint inhibitor. Conversely, ivonescimab’s bispecific regimen cut mortality by 34% and delivered a 79% twelve‑month overall‑survival rate, suggesting a robust efficacy signal with a potentially more favorable safety profile. While ADCs have historically struggled with stomatitis and pulmonary inflammation, newer generations are improving tolerability, and bispecifics may offer a cleaner adverse‑event landscape.

Regulatory trajectories further intensify the competition. Ivonescimab’s biologics license application targets a November PDUFA decision, whereas sac‑TMT benefits from a priority‑review voucher that could accelerate its FDA approval. Beyond head‑to‑head positioning, experts anticipate sequential or combinatorial regimens—using an ADC to prime the tumor microenvironment before introducing a bispecific—could become standard practice. Such strategies would expand market opportunities for both platforms, influencing payer formulary decisions and guiding future R&D pipelines toward integrated, multi‑modal cancer therapies.